Semax Results Timeline: What Studies Measured, and When

Questions about how quickly a compound "works" assume that the literature was designed to answer them. For Semax (a synthetic analogue of the ACTH(4-10) fragment), that assumption mostly does not hold. The published record is a scattered set of study types — resting-state brain imaging, a clinical report in ischemic stroke, and rodent behavioural, neurochemical and injury-model experiments — each with its own measurement schedule. This page summarises what was measured, in whom, and at which point in the study design. It does not predict what any individual would experience. A broader background overview is available in the PeptideU Semax learn page.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Why there is no single Semax "timeline"

A results timeline, in the clinical-trial sense, requires pre-specified endpoints measured at fixed intervals — week 4, week 12, month 6 — in a defined population. Most of the accessible Semax literature was not built that way. A 2018 report in Bulletin of Experimental Biology and Medicine examined effects of Semax on the default mode network of the brain, a measurement anchored to imaging sessions rather than to a multi-week endpoint schedule (PMID 30225715). A 2020 paper in Doklady Biological Sciences applied a functional connectomic approach to studying Selank and Semax effects, again framing the question as network-level brain activity rather than as symptom change over months (PMID 32342318). Those two reports describe what researchers looked at; neither establishes a schedule on which any functional benefit should be expected.

A broader 2026 review in Frontiers in Aging placed therapeutic peptides, including their proposed mechanisms and applications for healthy aging, in a wider context (PMID 42021992). Reviews of this kind summarise mechanism-level reasoning across many peptides; they are not a substitute for timepoint-level human outcome data on one compound.

Human literature: measurement points described

Brain-network imaging

The closest thing to a short-horizon human measurement in this set is the imaging work. The study on the default mode network assessed network-level brain activity in connection with Semax administration (PMID 30225715), and the connectomic analysis extended that approach by comparing Selank and Semax effects at the level of functional connectivity (PMID 32342318). The practical point for timeline questions is that these were session-anchored physiological measurements, not measurements of day-to-day cognition tracked over weeks. A change visible on a connectivity map is not the same category of finding as a change in memory, mood or work performance, and the literature cited here does not bridge that gap.

Ischemic stroke, by stage

The one clinical paper in this verified set that explicitly builds time into its design is a 2018 article in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, which examined the efficacy of Semax in the treatment of patients at different stages of ischemic stroke (PMID 29798983). "Different stages" is itself the timeline variable: the question asked was whether the stage of illness at which the peptide was administered mattered, rather than how many weeks until an effect appeared in a healthy person. Readers looking for general-population timelines should note that stroke-stage research describes a clinical population under medical supervision and cannot be extrapolated outside it.

Multi-component clinical protocols

Some clinical reports evaluate bundled interventions, which makes attributing any single component's time course impossible. A 2022 Russian report described results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis (PMID 36083821). When several treatments are delivered together, the study design does not isolate when — or whether — one element contributed to the observed change. That limitation is worth holding onto whenever a "timeline" is quoted from combination-protocol literature.

Animal literature: where the time structure actually lives

Most explicit timing information in the Semax record comes from rodent work, and it must be read as animal data. These studies are not human results and were not designed to generate human schedules.

Chronic administration and behaviour

A 2007 paper in Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova examined the effects of chronic Semax administration on exploratory activity and emotional reaction in white rats (PMID 17850024). The word that matters there is chronic: the design tested repeated administration rather than a single exposure, meaning the behavioural readouts described in the study followed a course of dosing, not one dose.

Developmental timing — when administration occurred, not how fast it acted

Two rodent papers treat timing as the independent variable. A 2005 study reported the dependence of long-lasting effects of the ACTH(4-10) analogue Semax on the time of its neonatal administration (PMID 15835535). A 2012 paper in Acta Naturae addressed correction of long-lasting negative effects of neonatal isolation in white rats using Semax (PMID 22708068). In both cases researchers measured outcomes well after the administration period ended, so the operative timeline is delayed and developmental: the question was whether early-life administration shifted something measurable much later, not whether an acute effect appeared within hours.

Early-life drug exposure models

A 2021 study in Neuropeptides reported that Semax, a synthetic ACTH(4-10) analogue, attenuated behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (PMID 33418449). Again, the measurement window sits downstream of an early exposure, and the endpoints were behavioural and neurochemical markers in animals rather than clinical outcomes in people.

Acute injury models and biomarker windows

The fastest-moving measurements in this set are biochemical. A 2023 F1000Research paper examined the effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models in male Sprague Dawley rats (PMID 41179234). Acute injury models measure molecular signals on a short horizon by design. Cytokine expression changes in an injured rat spinal cord are a mechanistic observation and do not describe a subjective timeline in an uninjured human.

What was measured, and when — at a glance

What the literature in this set does not establish

• No week-by-week human cognitive schedule. Neither imaging paper tracked cognition across weeks; both described brain-network measures (PMID 30225715, PMID 32342318).
• No healthy-population outcome timeline. The clinical report in this set concerned patients at different stages of ischemic stroke (PMID 29798983), a very different population from healthy adults.
• No human translation of rodent timing. The developmental and injury-model findings are animal data (PMID 15835535, PMID 41179234) and species differences in dosing, metabolism and behaviour are substantial.
• No dose-response curve across time. This page states no doses, because the verified literature summarised here is cited at the level of design and endpoint rather than quantified regimens.

Adverse Events and Tolerability: What Studies Report

The papers summarised on this page were framed around efficacy, mechanism and brain-network measurement rather than around structured safety reporting. The clinical paper on patients at different stages of ischemic stroke addressed efficacy in that population (PMID 29798983), and the rodent studies reported behavioural, neurochemical and cytokine endpoints rather than human tolerability data (PMID 17850024, PMID 41179234). A review of therapeutic peptides in gerontology discussed mechanisms and applications for healthy aging at a conceptual level (PMID 42021992). Stated plainly: large, long-term, controlled human safety datasets are not present in this verified set, and any timeline discussion should be read against that absence.

How to read timeline claims critically

1. Ask what the endpoint was. A connectivity map, a stroke-stage clinical rating and a rodent cytokine assay are three different things; the imaging work measured network activity (PMID 30225715) while the injury model measured IL-4, IL-10 and IL-13 expression in rats (PMID 41179234).
2. Ask who was studied. Patients at different stages of ischemic stroke (PMID 29798983) are not a proxy for healthy adults.
3. Ask whether timing was the variable or the schedule. In the neonatal work, timing of administration was the experimental variable itself (PMID 15835535).
4. Ask whether anything else was given. Bundled protocols cannot isolate a single component's contribution (PMID 36083821).

Taken together, this body of work describes mechanisms, brain-network measures and animal-model endpoints; it does not supply a validated human schedule of outcomes (PMID 32342318, PMID 22708068). Regulatory status also differs by country, and material sold for laboratory use is designated research-use-only rather than as an approved medicine in the United States.

References

• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Effects of Semax on the Default Mode Network of the Brain (Bulletin of Experimental Biology and Medicine, 2018)
• [The efficacy of semax in the tretament of patients at different stages of ischemic stroke] (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis] (Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury, 2022)
• Correction of long-lasting negative effects of neonatal isolation in white rats using semax (Acta Naturae, 2012)
• Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats) (F1000Research, 2023)
• [Dependence of long-lasting effects of the ACTH(4-10) analogue semax on the time of its neonatal administration] (Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2005)
• [Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats] (Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2007)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)